Background. The apolipoprotein E (ApoE)e4 allele is associated with an increasedrisk of senile and probablypresenileAlzheimer's disease. It is not yet clear whether the e4 allele also influencesthe duration/rateof progressof illnessand the severity of the dementia. Method. We have retrospectivelyexamineda seriesof ApoEgenotypedpresenileand senile autopsycases of Alzheimer'sdisease(AD) for length of illnessand severity of pathology. Results.We find no evidencethat ApoE genotype affects the rate of progressof AD, but the degree of pathologyat death may be increased.
genotype.
Alzheimer's disease (AD) is a neurogenerative disease characterised by fl-amyloid protein (flAP) deposits in senile plaques and cerebral blood vessel walls, and neurofibrillary tangles (NFTs) within neurons of the cerebral cortex and bippocampus. Apolipoprotem E (ApoE) is a 34 kDa proteinthat is involvedin cholesterol and triglyceride transport, mediating their clearance from plasma by interaction with low density lipoprotein receptor. ApoE exists asthree principal isoforins E2, E3 and E4 which are encoded by three separate alleles â‚¬¿ 2, â‚¬¿ 3 and â‚¬¿ 4 ata geneon chromosome 19. A highly significant association between familial and sporadic late-onset AD and the â‚¬¿ 4 allele of the ApoE gene has been described by a large number of groups worldwide. By contrast, the association of the â‚¬¿ 4 allele with early-onset AD is less clear-cut. However, recent studies suggest that ApoE â‚¬¿ 4 may be a risk factor for familial (van Duijn eta!, 1994) and/or sporadic (Okuizumi eta!, 1994 ) early onset AD. Roses et a! (1994) have suggested that in population terms the high risk â‚¬¿ 4/â‚¬4 genotype lowers the age distribution of AD by more than 20 years compared with the low risk â‚¬¿ 2/â‚¬3 genotype, with the more prevalent â‚¬¿ 4/â‚¬3 and â‚¬¿ 3/â‚¬3 genotypes showing intermediate age distributions. The phenomenon is analogousto,butless pronouncedthan,trisomy21
where the majority of cases develop AD before the age of 65.
While the presence of the â‚¬¿ 4 allele appears to be associated with an earlier age of onset of AD, the effect of ApoE genotype on rate of progression of the disease is less evident. A definitive answer to this question will require prospective longitudinal studies in which the progression of the disease is assessed at regular intervals betweenonset and death in patients grouped according to their ApoE genotype. In the meantime the evidence must be retrospective, and duration of dementia used as a measure of rate of progression. Assessing age of onset of AD in the elderly is difficult and given the very high mortality from other causes in this age group, the length of time between apparent onset and death is not a reliable index of the rate of progression of AD. It is also important to know if there are any differences in severity of disease at death between the different ApoE groups. If the neuropathology is more severe, the implication, since degree of dementia correlates with the numbers of plaques and tangles, is that patients with AD associated with â‚¬¿ 4 allele may be more profoundly demented in the later stages of their disease than those with non-â‚¬4-allele associated AD. Schmechel et a! (1993) (mean age at death 64 years). All brains were examined by a consultant neuropathologist (Dr A. Gordon) and satisfied NINCDS criteria for definite Alzheimer's disease (McKhann et a!, 1984) . Full clinical histories were available on the 19 presenile cases, including details from at least one first-degree relative as to when symptoms of dementia began. For 43 of the 66 senile cases documentation was available and age of onset and duration of illness were determined by at least one consultant psychiatrist.
Neuropathological examination
The weight of the formalin-fixed right hemisphere was available for all cases. All brains were examined for evidence of Alzheimer's disease, macroscopically and microscopically, using haematoxylin and eosin and von BraunmUhl's silver technique for neuritic plaques and NVFs. In 14 presenile and 51 senile cases, plaque and NET counts were separately graded on a 4-point scale in sections of temporal cortex, frontal cortex and hippocampus. All gradings were made by the same neuropathologist (A. Gordon) (see Table 2 ).
ApoE genotyping
ApoE genotyping was performed on 19 cases of presenile and 66 cases of senile AD and on 47 neuropathologically validated non-demented controls. The method employed was essentially as described by Wenham eta! (1991) , with the exception that 6% metaphor agarose gels were employed for product analysis. PCR conditions were also modified to allow use of a Hybaid thermocycler on tube control. Optimised conditions employed 200 ng genomic DNA with denaturation at 95Â°C for 15 s, annealing at 60Â°Cfor 1 mm and extension at 72Â°Cfor 30 s (cycles 1â€"10), 45 s (cycles 11â€"20), Population data was also available for ApoE allele frequencies in the Scottish population (Cumming & Robertson, 1984) . Table 1 There were no significant differences betweenthedurationof dementiain thedifferent genotypes in either the presenile or senile cases. Table 2 compares the plaque and NFT scores in three ApoE genotypes (â‚¬2/3or 3/3; â‚¬¿ 3/4; â‚¬¿ 4/4) in the presemle and senile cases. In the senile group, plaque and NET scores tended to increase with increasing â‚¬¿ 4 copy number in the temporal and frontal cortex; no such tendency was present in the hippocampus. In the presenile group, there were too few cases in the individual genotypes to allow for any conclusion. Overall no statistically significant differences were observed.
Results

Brain weights
Right half-hemisphere brain weights (g) were compared according to gender and ApoE genotype. There were insufficient cases to allow comparison within the presenile groups. In the senile group, there were no significant differences (mean Â± s.d., 1-test,
P>0.05) between half-brain weights in the â‚¬¿ 3/3 cases
(women = 564 Â± 55, n = 17; men = 617 Â± 67, n =10), â‚¬¿ 314 cases (women = 588Â± 46, n = 20; men = 660Â±40, n = 4) and â‚¬¿ 4/4 cases (women= 590Â± 73, n = 9; men=685Â±55, n=4 (1) or 3/3 (2â€"3) (2â€"3) (2-3)(1â€"3)66Â±4 F(3) @2/4 2.8 2.4 2.6 2.3 2.32.1M (6) or 3/4 (2-3) (1â€"3) (2â€"3) (1â€"3) (1-3)(0-3)70,71 F(1) t4/4 3 3 3 2.5 2.52.5M (1) (2-3) (2-3)(2-3)Senile AD 83Â±7 F(11) t3/3 2.4 2.1 2.0 1.6 2.50.8M (7) (1â€"3) (1â€"3) (0â€"3) (0-3) (1-3)(0â€"3)82Â±4
F (18) @3/4 2.5 2.2 2.2 1.8 2.21.0M(4) (1â€"3) (1â€"3) (1â€"3) (1â€"3) (1â€"3)(0â€"3)79Â±5 F(7) t4/4 2.6 2.2 2.5 1.8 1.91.4M (4) (1-3) (1-3) (1-3) (0-3) (0-3)(0-3) Table 1 ApoE gene frequenciesand clinical features of AD cases and controls 1. meanÂ±s.d
2. mean(range)plaqueandtanglenumbers. Two or threemicroscopicfieldsassessed pertissuesection,0 = none,1= few, 2=many, 3=very many.
x 125 magnification for plaques, x 313 magnification for tangles, Von BraunmÃ¼hl's silver technique.
Discussion
ApoE genotypes and age of onset of AD The gene frequencies in our senile AD and control groupsaresimilar tothosereported elsewhere: there is two and a half times as much â‚¬¿ 4 allele in senile AD as in non-demented controls. A gene frequency for â‚¬¿ 4 of 0.47 in our presenile group is the highest yet reported, but is close to the figure of 0.41 observed by Van Duijn et a! (1994) among familial early-onset AD and supports the view that ApoE â‚¬¿ 4 allele is enriched among presenile/early-onset AD. In our group of 43 senile AD cases we found no relationship between age of onset or duration of dementia and â‚¬¿ 4 copy number, unlike Poirier et a! (1993) , who in a larger group of 91 senile cases observed a significant decrease in age of onset with increase in â‚¬¿ 4 copy number. However, determining the timing of onset of AD in the elderly is hazardous;
sometimes it is associated with an abrupt change; more often it goes unnoticed for many years. Therefore, given in addition the high mortality from other causes in this age group, estimates of length of time from onset to death are a poor guide to duration of illness in senile AD. For this reason we have analysed the presenile early-onset cases separately. Not only was time of onset well documented by at least one first-degree relative, but inall cases AD was almostcertainly theprimary cause of death. The most striking feature was the wide range of duration of illness with AD among cases both heterozygous and homozygous for â‚¬¿ 4, even when those with family history of illness are excluded. The clinical course ranged from 1.5 to 11
years and was notdependent on ageofonset. Indeed the overall pattern is indistinguishable from that observed in early-onset AD as a whole. The implications of these findings seem clear. Since we cannot observe an effect of â‚¬¿ 4 on rate of progress of AD, even in this subgroup where, for reasons indicated, it should be easiest to observe, we conclude that any effect â‚¬¿ 4 may have on rate of progress in the AD population as a whole is likely to be small and of minimal clinical importance. â‚¬¿ 4 allele and severity of AD Table 2 shows a non-significant trend for increasing neuritic plaque and NFT scores with increasing â‚¬¿ 4 load in temporal and frontal cortex in the senile AD groups. Our results are similar to, but less pronounced than, those of Schmechel et a! (1993) who found only mildly elevated NFT counts in â‚¬¿ 4 homozygotes, but a significant elevation of neuritic plaque counts in the temporal and frontal cortex, but not in the hippocampus. We relied upon a grading system which would tend to reduce the range of our results, whilst Schmechel counted plaque numbers.
Like Schmechel, we found no association between ApoE allele status and brain weight. We have not performed immunocytochemistry for fi amyloid and cannot comment on Schmechel's observation of increased j3-AP deposition in AD patients with the â‚¬¿ 4 allele. We do however conclude that while the â‚¬¿ 4 allele may be associated with increased fl-AP deposition, overall it appears that patients homozygous for the â‚¬¿ 4 allele do not have a markedly more severe neuropathology (assessed by brain weight and silver stained neuritic plaques and NFTs) than patients homozygous for â‚¬¿ 3.
This suggests that the clinical impact of these differences is likely to be modest.
Conclusions
We fmd no evidence, even in early-onset cases where it should be easier to observe, if present, that possessing an ApoE allele is associated in AD with a different rate of progress of disease, assessed by duration of illness. These data, together with the absence of any observed effects on duration of illness and age at death in late AD, reported by Schmechel et a!, suggests that the rate of progress of AD as a whole is independent of the ApoE genotype. We also find that ApoE allele, even in homozygotes, is associated with a neuropathological phenotype only marginally greater than that observed among other ApoE genotypes.
Two conclusions emerge from this study. First, it seems that while possessing one or more ApoE â‚¬¿ 4 alleles definitely increases your risk of developing AD, the dementia itself will be broadly similar in terms of its length and severity to non-ApoE â‚¬¿ 4-associated disease. The second, and perhaps the more important, concerns the design of treatment studies. Since ApoE genotype does not significantly affect the duration and severity of illness, therapeutic trials are much easier than if each group had to be analysed separately.
